Drug Buyers Cut New, Smaller Antitrust Deal With Celgene
Consumers, cities and union benefits are taking another shot at settling class action claims that Bristol-Myers Squibb's Celgene unit monopolized cancer drugs by proposing a pared down $34 million deal that...To view the full article, register now.
Already a subscriber? Click here to view full article